<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>10944975</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Banegas Banegas, J R</dc:author>
<dc:author>Tomás Abadal, L</dc:author>
<dc:author>Villar Alvarez, F</dc:author>
<dc:author>Plaza Pérez, I</dc:author>
<dc:author>Rodríguez Artalejo, F</dc:author>
<dc:author>Mata López, P</dc:author>
<dc:author>Maiquez Galán, A</dc:author>
<dc:author>Gil López, E</dc:author>
<dc:author>Casasnovas Lenguas, J A</dc:author>
<dc:author>Pérez Jiménez, F</dc:author>
<dc:description xml:lang="en">The document "Cholesterolemia Control in Spain, 2000: A Tool for Cardiovascular Disease Prevention" reviews the current evidence on cardiovascular disease prevention and the therapeutic advances achieved in recent years, in order to aid risk-based clinical decision-making. Cardiovascular diseases rank as the first cause of death in Spain. Their demographic, health and social impact is increasing and it is likely to continue to do so in the next decades. Appropriate treatment for high blood cholesterol and other major risk factors is crucial in cardiovascular disease prevention. Individual risk stratification is essential to determine follow-up periodicity and treatment. Priorities for the control of cholesterolemia and the consequent cardiovascular risk are based on risk stratification. In primary prevention, the therapeutic objective in high risk patients has been established as LDL-cholesterol &lt; 130 mg/dl. In secondary prevention, drug treatment is indicated when LDL-cholesterol &gt; or = 130 mg/dl and the therapeutic objective is LDL-cholesterol &lt; 100 mg/dl. Statins are first line drugs for treatment of high blood cholesterol. In moderate-severe hypertriglyceridemia or low HDL-cholesterol, fibrates are preferred. In acute coronary syndrome, hypolipemiant treatment, should be started as soon as possible, when indicated. Secondary prevention programmes that continually provide good clinical and risk factor control should be provided to coronary heart disease patients.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 Jun </dc:date>
<dc:title xml:lang="es">Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular.</dc:title>
<dc:title xml:lang="en">[Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention].</dc:title>
<dc:publisher>Revista espanola de cardiologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
